Dylann Cohn-Emery | Authors


Pre-Emptive Treatment May Be Superior to Reactive Treatment of Hand–Foot Reactions in mCRC

February 25, 2021

A preplanned analysis of the Regorafenib Dose Optimization Study in patients with metastatic colorectal cancer showed using pre-emptive clobetasol to treat hand–foot skin reactions was more effective than treating this adverse event reactively.

TIVO-3 Trial End Point Q-TWiST Increased With Tivozanib in RCC

February 12, 2021

The VEGF tyrosine kinase inhibitor tivozanib hydrochloride demonstrated a significantly increased quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy in patients with metastatic renal cell carcinoma compared with sorafenib in the phase 3 TIVO-3 trial.